TLDR Apremilast helps regrow hair in hard-to-treat alopecia areata.
The study concluded that Apremilast, an oral phosphodiesterase 4 inhibitor, was effective in treating refractory alopecia areata (AA). The research involved a small cohort of patients who had not responded to conventional therapies. The results showed significant hair regrowth in these patients, suggesting that Apremilast could be a promising treatment option for those with difficult-to-treat AA. The findings provided hope for improved management of this challenging autoimmune condition.
23 citations,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
77 citations,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
52 citations,
December 2014 in “Journal of Dermatological Science” Apremilast may help treat hair loss in alopecia areata.
148 citations,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
May 2018 in “Journal of cosmetology & trichology” Combining platelet-rich plasma therapy with prostaglandin-F eye drops can significantly regrow hair in alopecia universalis.
